Article Text
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q Does risperidone prevent relapse compared with placebo for children with autism spectrum disorders?
METHODS
Design:
Randomised controlled trial.
Allocation:
Concealed.
Blinding:
Double blind.
Follow up period:
Thirty two weeks.
Setting:
Groningen and Utrecht University Child and Adolescent Psychiatry Centres; time period not stated.
Patients:
Thirty six children aged 5–17 years with an autism spectrum disorder (Autism Diagnostic Interview-Revised plus clinical judgement) enrolled in the open label phase, 24 children who responded to risperidone were randomised. Other enrolment criteria: at least moderate disruptive behaviour (tantrums, self-injury, and/or aggression) …
Footnotes
For correspondence: Dr Pieter W Troost, Child and Adolescent Psychiatry Center, Hanzeplein 1, 9713 GZ Groningen, the Netherlands; p.troost{at}accare.nl
Source of funding: Korczak Foundation.